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Introduction
Hepatitis C virus (HCV) infection is a major public health issue.
Global prevalence of HCV is approximately 180 million people [1] .
Central Africa has the second highest HCV prevalence: 6.0% of adults overall [2] . In Burundi, HCV prevalence is estimated up to 8.2% [3] . There are at least six genotypes throughout the world, each of them containing subtypes, according to the nucleotide divergence [4] . HCV genotype identification is clinically important to tailor the dosage and duration of treatment because distinct therapeutic approaches are required for each genotype [5] .
Duration of treatment for a maximal sustained virological response (SVR) rate depends on genotype. In recent years, there has been an increasing interest in HCV subtype for SVR. Indeed, the subtype 1a could be associated with a lower response to anti-HCV therapy than subtypes 1b, 4a, and 4d [6, 7] . Up to now, there is no study assessing HCV genotypes and subtypes in Burundi. A further issue is that the laboratory techniques are validated based on American and European samples and could not be well adapted to african samples. The aim of our study was to determine HCV genotypes and subtypes in Burundi and to highlight the difficulties related to LiPA Method, widely used, about African samples.
Methods

Study population:
The study population consisted of consecutive willing patients aged ≥15years; attending medical cares in CEMADIF since January to May 2013. We included patients with anti-HCV antibodies positive. We excluded patients under interferon treatment or who have achieved the treatment with a SVR.
Study design:
This was a cross sectional study. Socioeconomic and clinical data were collected by interview followed by a clinical examination done by a physician. After, patients were directed to the laboratory for blood sampling. In CEMADIF laboratory, all samples were collected and frozen by 4 hours. 122 (68.1%) were married while 31 (17.3%) were widows (ers).
The patients were native of all provinces of the country. 103
(57.5%) resided in Bujumbura City. The HCV RNA was detected among all patients with the extremes of 113UI/ml (2.05log) and 20
208194 UI/ml (7.30log). in Cameroon, the HCV-4 prevalence is 31% [11] .
Another important finding is that the 4h and 4e subtypes are the most common in our country. The most common subtype in Egypt is 4a, in Gabon 4c and in Cameroun 4f [11, 12] . Table 3shows different subtypes in different countries [11] [12] [13] [14] [15] [16] [17] [18] [19] . These findings further support the idea that the origin, evolution, and dynamics of West Africa before spreading to other regions [13, [19] [20] [21] .
It seems also important to emphasize that the LiPA method was unable to subtype a number of HCV-4 in our study. This finding was unexpected and suggests that the LiPA method, commonly used throughout the world, could be not adapted to African samples, particularly in countries where HCV-4 is predominant. Likewise, other authors have reported the same difficulty to subtype HCV-4, but in lower level than in our study [11] . The producers of reagents should be aware some more to guarantee a large diagnostic efficiency. At last, another interesting finding was that the genotype 3, not reported in the countries of eastern and central Africa, is however, found at 1.7% in our study.
Conclusion
The genotype 4 is the most frequent in Burundi. The subtype 4h seems to be predominant. Further, the genotype 3 rare in central Africa, is found in our country at 1,7%. The producers of reagents should be aware some more to assure a large diagnostic efficiency.
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